Shares of Sophiris Bio Inc. sank in Monday’s extended session after the biopharmaceutical company said it is planning a secondary offering. It will also sell warrants, a type of security that allows the holder to buy the company’s underlying stock at a fixed price. Piper Jaffray & Co. is serving as a book-running manager for the deal. Sophiris shares tumbled 27% after hours.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News